Beam Opens a Trade-Secret Dispute Around AATD Base Editing

Company Beam Therapeutics / YolTech Therapeutics / Serapha Bio Event Type Litigation / Trade Secret Complaint Modality In Vivo Base Editing (LNP-Delivered) Asset BEAM-302 / YOLT-202 Target SERPINA1 (E342K) Disease Area Alpha-1 Antitrypsin Deficiency Summary Beam Therapeutics filed a federal complaint against former employee Zi…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

GSK Acquires Nuvalent for $10.6B
Curium Agrees to Acquire Lantheus for Up to $8 Billion
Typewriter Launches with $56 Million for All-RNA Gene Insertion
Ligand Funds AvenCell CAR T Pipeline